

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-12 (Canceled).

Claim 13 (Previously presented) A purified monoclonal antibody which specifically recognizes a peptide consisting of the amino acid sequence of SEQ ID NO:2.

Claim 15 (Previously Presented) A therapeutic composition for increasing the concentration of antibodies to aglycoprotein 10B antigenic epitopes in a patient in need thereof, the composition comprising a peptide selected from the group consisting of the peptide consisting of SEQ ID NO:1, the peptide consisting of SEQ ID NO:2, and combinations thereof.

Claims 16-23 (Canceled).

Claim 24 (Previously presented) A kit for determining the concentration of aglycoprotein 10B antigenic epitopes present in blood of a patient comprising at least one blood collection tube or pipette and a purified monoclonal antibody that specifically recognizes the peptide consisting of SEQ ID NO:1 or the peptide consisting of SEQ ID NO:2 wherein said antibody is coated on the inner surface of said collection tube or pipette.

Claim 25 (Previously presented) A kit for determining the concentration of aglycoprotein 10B antigenic epitopes present in blood of a patient comprising at least one blood collection tube or pipette and a peptide consisting of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

Claim 26 (Previously presented) The kit of claim 25 wherein the peptide is coated on the inner surface of the tube or pipette.

Docket No: 13793/468031 (formerly 09425/468031)

Serial No: 10/642,587

Response to Final Office Action with RCE

Claim 27 (Previously presented) An isolated nucleic acid encoding a peptide consisting of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

Claims 28-31 (Canceled).

Claim 32 (New) The therapeutic composition of claim 15 further comprising a pharmaceutically acceptable carrier.